Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The US Food and Drug Administration (FDA) has approved Boehringer's Combivent respimat, an inhalation spray for the treatment of chronic obstructive pulmonary disease (COPD).
Subscribe to our email newsletter
Combivent respimat, which is a propellant-free inhaler product uses a slow-moving mist to deliver the same active ingredients of Combivent Inhalation Aerosol in a metered dose inhaler (Combivent MDI).
Combivent MDI and Combivent respimat are short-acting bronchodilator products that offer two different medicines in a single inhaler.
The efficacy of the spray was studied in a 12-week, randomized, double-blind, placebo and active-controlled clinical trial.
The data demonstrated that Combivent respimat was clinically comparable to Combivent MDI, in terms of FEV1, which is the maximal amount of air that can be forcefully exhaled in one second.